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Abstract
The estrogenic and antiestrogenic potential of perfluorooctanoic acid (PFOA) was assessed using
an immature mouse uterotrophic assay and by histologic evaluation of the uterus, cervix and
vagina following treatment. Female offspring of CD-1 dams were weaned at 18 days old and
assigned to groups of equal weight, and received 0, 0.01, 0.1, or 1 mg PFOA/kg BW/d by gavage
with or without 17-β estradiol (E2, 500 μg/kg/d) from PND18-20 (n=8/treatment/block). At 24 hr
after the third dose (PND 21), uteri were removed and weighed. Absolute and relative uterine
weights were significantly increased in the 0.01 mg/kg PFOA only group. Characteristic
estrogenic changes were present in all E2-treated mice; however, they were minimally visible in
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the 0.01 PFOA only mice. These data suggest that at a low dose PFOA produces minimal
histopathologic changes in the reproductive tract of immature female mice, and does not
antagonize the cellular effects of E2.
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1. Introduction
Perfluorooctanoic acid (PFOA) is a synthetic, 8-carbon member of the perfluoroalkyl acid
(PFAA) family of fluorinated organic compounds, and has become one of the most
ubiquitous chemicals found in the environment [1]. PFOA is currently applied or is a final
breakdown product of polymers used as surface protectors and coatings for textiles, and in
numerous industrial products including lubricants, paints, polishes, surfactants, and flame-
retardant foams [1–3]. It is ubiquitously detected in the environment and in the serum of
wildlife and humans [4–6]. PFOA is also measurable in surface [7, 8] and drinking water
[8], and is a global contamination problem of public health concern.
PFOA is found at very low levels in both the environment and the general U.S. population
and individual exposure has been documented via inhalation, dermal absorption, and
ingestion [1]. The compound transfers to the unborn offspring across the placenta and breast
milk is thought to be a source of PFOA exposure for infants [9–11]. In lactating mice, milk
has been shown to be a route of exposure for nursing pups [12, 13]. PFOA has a half-life of
2–4 years in humans and has been reported to cause developmental, toxic and long-term
adverse outcomes in aquatic and laboratory animals [1, 4, 13–15].
The mechanism of PFOA-induced effects, primarily in the liver, has traditionally been
thought to occur strictly through a peroxisome proliferator–activated receptor α (PPARα)
mechanism [16]; however, recent animal and epidemiologic data suggest that PFOA may
cause endocrine disruption [14, 15, 17–19]. PFOA has been reported to alter female pubertal
timing in multiple strains of mice [12, 20], and has recently been reported to delay pubertal
timing in girls, but not boys. In a report from the C8 Science Panel [21], data collected on
the potential health effects in US regions once polluted with PFOA suggest that delayed
puberty in girls (measured as either serum estradiol >20 pg/mL or self-reported menarche)
was associated with the highest levels of serum PFOA. In a British cohort of girls, prenatal
exposure to PFOA and a related compound was not associated with self-reported age at
menarche [22]. Neither of these studies addressed pubertal breast timing, but disrupted
mammary gland development of female mice following low-dose prenatal exposure to
PFOA has been reported [23, 24]. PFOA treatment can up-regulate protein levels of estrogen
receptor alpha (ERα) and proliferating cell nuclear antigen (PCNA) in the mammary glands
of wild-type C57Bl/6 and PPARα knock-out mice [14]. Women with high serum
concentrations of PFOA were reported to have an earlier onset of menopause compared to
their counterparts who have lower serum PFOA levels [17]. PFOA can also increase the
activity of estrogen-responsive genes in fish [25].
Because of these endocrine-related findings and others (reviewed in [26] ), we assessed the
estrogenic or antiestrogenic potential of low doses of PFOA on female reproductive tissues
using an immature mouse uterotrophic assay and by evaluating the histomorphology of the
uterus, cervix and vagina following treatment.
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2. Materials and Methods
2.1 Chemicals
PFOA, as its ammonium salt (>98% pure), was acquired from Fluka Chemical (Steinheim,
Switzerland). PFOA was prepared fresh daily in deionized water. Mice received either
distilled water as vehicle or 0.01, 0.1, 1 mg PFOA/kg body weight (BW)/d by oral gavage
from PND 18–20.
17β-estradiol (E2) was acquired from Sigma-Aldrich (St. Louis, MO). E2 was prepared in
corn oil and mice received either corn oil as vehicle or 500 µg/kg BW/d by subcutaneous
injection from PND 18–20 [27].
2.2 Animals
Timed-pregnant CD-1 mice delivered their young on day 19 of gestation at Charles River
Laboratories (Raleigh, NC). At birth (day 1), all pups were sorted by sex and randomly
redistributed so that all litters were normalized to 12 female pups per dam (not necessarily
their own). The dams and female pups were received at the U.S. EPA NHEERL
Reproductive Toxicology Facility (RTP, NC) on postnatal day 12 (PND 12). Upon receipt,
litters were standardized to 10 female pups per dam. Litters were housed in polypropylene
cages lined with Alpha-dri bedding (Shepherd Specialty Papers, Kalamazoo, MI). All
animals were housed under controlled lighting (12:12 hour light:dark), temperature (20–
24°C), and relative humidity (40–60%) conditions. Fresh de-ionized water and NIH-31
rodent diet (an open formula, autoclavable, natural-ingredient rodent diet with estrogenic
activity at ≤ 140 ppm, Zeigler Brothers, Inc., Gardners, PA) were provided ad libitum. All
animal procedures complied with US EPA NHEERL Institutional Animal Care and Use
Committee guidelines for care and euthanasia.
2.3 Uterotrophic Assay Study Design
Following the protocol of Padilla-Banks and co-workers [28], pups were weaned on the
morning of PND 18 and randomly assigned to one of eight treatment groups (n=8 per
treatment group per block). Replicate A (block1) included the treatment groups corn oil
vehicle or E2 in corn oil (500 µg/kg/d, s.c.) alone, PFOA alone (0, 0.01, 0.1, 1 mg/kg BW/d,
gavage), or PFOA (0, 0.01, 0.1, 1.0 mg/kg BW/d, gavage) + E2 (500 µg/kg/d, s.c.).
Treatments were given for 3 consecutive days starting in the afternoon of PND 18 with uteri
collected on PND 21. A second replicate of animals (block 2; B) was run in this identical
design to confirm the effects in replicate A. A third replicate (block 3; C), in the identical
dosing regimen of replicate A, was conducted to obtain the entire reproductive tracts from
females in these treatment groups for further histological evaluation only (these uteri were
not weighed).
2.4 Tissue Collection
Mice were weighed daily and prior to tissue collection. Euthanasia was completed by
decapitation on the morning of the fourth day (PND 21) and trunk blood was collected by
funneling the blood into Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ). For
blocks A&B, an incision was made in the skin and abdominal muscle and cervix separated
from the vaginal fornix. Because fluid imbibition is an estrogenic response, special care was
taken to retain all uterine luminal fluid. The uterus was removed after cutting by gently
lifting the tissue anteriorly and dissecting it from the mesometrium. An incision was made in
the uterotubal junction to preserve the uterine horns and avoid loss of uterine fluid [27]. The
uterus was immediately weighed, properly oriented in a histocassette, fixed in 10% buffered
formalin (Fisher Scientific, Fair Lawn, NJ), and processed for sectioning and
histopathologic examination. Replicate C tissue resections included the entire female
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reproductive tract (uterus, cervix, vagina) as a single unit. These tissues were fixed as stated
above and trimmed so that longitudinal sections through the uterus, the utero-cervical
junction, cervix and vagina could be prepared.
2.5 Histopathology
Fixed uterine samples were processed by routine methods and embedded in paraffin blocks.
Five-micron tissue sections were cut, mounted on glass slides and stained with hematoxylin
and eosin (H & E). Slides containing H & E stained tissue samples were evaluated for
pathologic changes using conventional light microscopy.
Each H&E-stained tissue section was reviewed for histopathologic changes and
semiquantitatively evaluated by assigning a severity score for changes observed in the uterus
(endometrial edema; endometrial epithelial hyperplasia of the mucosa or glands;
hypertrophy/hyperplasia/edema of the myometrium), and cervix and vagina (mucification,
mucosa; squamous hyperplasia and cornificaton, mucosa; edema, submucosa/stroma) by a
pathologist without knowledge of treatment groups. The cervix and vagina were scored
together due to consistent and similar histological findings in the two regions. Severity
scores ranged from 0–4. A score of 0 indicated an absence of demonstrable histopathologic
changes and was considered to be within normal range. A score of 1 (minimal) denoted a
subtle histopathologic change present that barely exceeded the normal range; 2 (mild)
indicated the histopathologic change was present, however, it was not pronounced and of
limited severity; 3 (moderate) denoted a histopathologic change was present and was
pronounced; and 4 (severe) indicated a histopathologic change was present at its greatest
extent and was very pronounced and significant.
2.6 Calculations
The uterine wet weight (UWW):body weight (BW) ratios were calculated for each animal
by dividing the uterine wet weight by the body weight. Data were evaluated for exposure-
related effects using general linear model analysis of variance (ANOVA) in SAS 9.1 (SAS
Institute, Inc. Cary, NC), with statistical significance at p<0.05. All data were assessed via
one- or two-way analysis of variance with Dunnett’s posthoc test. Block effect was
evaluated. The average body weight and the average uterine wet weight for each treatment
group were also calculated and compared.
For histopathology severity score comparisons in the uterus, cervix and vagina, the Mann-
Whitney test with a one-sided p-value was used to determine statistical significance (p<0.01
or p<0.05) between the mean severity scores of individual and overall histopathological
changes for all treatment groups and to compare each treatment group with respective
controls.
3. Results
3.1 Absolute and Relative Uterine Wet Weight (UWW)
There was no effect of PFOA or estradiol on body weight in these studies (Table 1). With
the exception of mice administered 0.01 mg/kg PFOA, the UWW (absolute) and UWW:BW
ratios (relative uterine weight) for mice administered varying doses of PFOA alone, once
daily for 3 days from PND 18–20, were not significantly different from those of the control
group. The absolute and relative UWWs of mice administered 0.01 mg/kg PFOA were
significantly greater than those of the PFOA control group (p<0.05; Figs. 1 and 2; Table 1).
Similar effects were evident in each block (A and B; no block effect). The 0.01 mg/kg
PFOA exposure produced a nearly 50% increase over control in UWW and UWW:BW
ratio. The absolute and relative UWW of groups administered PFOA + E2 were not
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significantly different from the respective controls. The increase in weight due to estradiol
administration is shown for UWW in Table 1, and the fold over control varied from 7.14 to
8.30 for the UWW:BW ratios, as expected.
3.2 Histopathology
The uterus, cervix and vagina of E2-treated mice showed several characteristic, estrogenic
changes. In the uterus, there was moderate edema of the endometrium characterized by
separation of the endometrial stromal cells, moderate thickening (hyperplasia) of the uterine
mucosal and endometrial glandular epithelia, and hypertrophy of the smooth muscle cell
layers (Fig. 3) Squamous hyperplasia and cornification of the vaginal and cervical
epithelium in response to E2 was also observed. There were no significant differences in the
mean severity scores for individual or overall histopathologic changes in the uterus, cervix
and vagina between the groups of E2-treated mice (Figs. 4 and 5).
Mice treated with PFOA alone had minimal histopathologic changes in the uterus, cervix
and vagina that were similar to but far less severe than those observed in E2-treated mice
(Fig. 3). In the uterus, there was minimal to mild endometrial and myometrial edema in
addition to minimal thickening (hyperplasia) of the uterine mucosal and endometrial
glandular epithelia, and smooth muscle layers. These uterine changes were present in some,
but not all sections from the PFOA treatment groups. There was also focal minimal stromal
edema of the cervix, and the vagina had focal areas of mucification, but cornification and
squamous hyperplasia of the cervical and vaginal mucosae were not present to any
significant degree. All vaginal and cervical changes noted were present in some, but not all
sections from the PFOA treatment groups. The mean severity scores for the uterus showed
the 0.01 PFOA alone group had significantly increased histopathologic changes in the
endometrium and myometrium compared to the controls and the 0.1 and 1.0 PFOA alone
groups (Fig. 4). The mean severity score for overall estrogenic changes in the uterus was
significant in the 0.01 PFOA group compared to controls and the 0.1 PFOA group. These
hsitopathologic alterations may have contributed to the increased uterine weight detected in
the 0.01 PFOA group. In the cervix and vagina, the mean severity scores for mucification
and overall changes were significantly increased in the 1.0 PFOA only group compared to
the controls (Fig. 5). PFOA induced varied dose effects in the uterus versus the vagina and
cervix; whereby there was a nonmonotonic (inverted-U) response for overall histopathologic
changes in the uterus, and a linear response was observed in the vaginal and cervical tissues
(Figs. 4B and 5B).
PFOA had no antiestrogenic effects when co-administered with E2 and characteristic
estrogenic changes were observed in the uterus, cervix and vagina as described above (Figs.
3, 4 and 5).
4. Discussion
This study, to our knowledge, is the first to describe the histopathologic changes in the
immature mouse uterus, cervix and vagina following low doses of PFOA administration
with and without E2. Earlier carcinogenicity studies in adult rats, in which there is
descriptive histopathology, have shown that PFOA induces tumors of the liver and pituitary
gland in males and females. In the same study, increased incidences of mammary gland
tumors in females, and testicular Leydig cell tumors in males were also noted [29].
However, a reexamination of mammary tissues from that study showed that the incidence of
mammary gland neoplasms was similar to that of historical controls for female SD rats [30].
Nevertheless, these earlier findings suggest that hormone responsive tissues in both male
and female adult rats may be the targets for the effects of PFOA following long-term adult
exposures.
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PFOA is a synthetic perfluorinated compound that does not occur naturally in the
environment, yet it is a global contamination problem and a public health concern [1–3].
Recent studies suggest that PFOA may pose a threat as a weak environmental xenoestrogen
following prenatal exposures [25, 31, 32]. Using an immature mouse uterotrophic study that
has been directly compared to a similar assay in Sprague-Dawley rats [28], we found a slight
albeit significant increase in uterine weight in the lowest exposure group (0.01 mg PFOA/
kg) that coincided with gross enlargement at the utero-cervical junction in most 0.01 and a
smaller fraction of 0.1 and 1.0 PFOA-exposed animals in blocks A and B and minimal, but
significant histopathologic changes compared to respective controls in (the histopathology
only) block C. The effects of stress on the young mice used in this study could not be ruled
out; although, we did not see much variation in uterine weight data between blocks A and B,
and the histopathology findings (block C) in the uterus of the 0.01 PFOA-exposed only
group correlated well with the increased uterine weight data observed in mice in blocks A
and B.
The E2-induced uterine weight change reported in previous studies [28] using the immature
CD-1 mouse was 6.5-fold between control and 500 µg/kg E2, whereas that same dose in the
current study induced nearly 9-fold stimulation of uterine weight gain. The mean UWW for
20 day old control mice in the previous study [28] was 0.011±0.001 g and in our study on
PND 21, it was a similar, 0.013±0.001 g (mean±SEM). These studies reported low
variability in uterine wet weight. Thus, in the present study, a nearly 7 mg increase in uterine
wet weight between the 0 and 0.01 mg PFOA/kg exposure groups represents a significant
50% increase, whereas 20–25% change from control were evident in the 0.1 and 1.0 mg
PFOA/kg only groups. The nonmonotonic or inverted-U dose response observed in the
uterus of the PFOA/kg only groups, may possibly be attributed to the ability of some
environmental agents at low doses to mimic the normal mechanisms controlling a response.
Also, when a low dose of an agent rises into a higher range it may function to activate
different pathways and create a negative feedback loop which then may in turn shut down
the original response, or if at high enough level result in overt toxicity and/or cell death.
Further molecular and mechanistic studies, beyond the scope of this paper, are needed to
delineate the mode of action of PFOA in the uterus.
It has been shown that PFOA is a potent inducer of vitellogenin in vivo, weakly binds the
ER similar to other environmental estrogens, and can enhance human ERα-dependent
transcriptional activity in rainbow trout [31]. Previously, we and other investigators have
reported that PFOA treatment could disrupt development or alter gene expression in
mammary gland tissue, another estrogen responsive organ [14, 15]. Additionally, male and
female freshwater minnows exposed to PFOA developed testicular oocytes and ovarian
degeneration, respectively, both of which are indicators of estrogenic activity [33].
PFOA upregulates protein levels of ERα and PCNA in mammary glands of wild-type
C57Bl/6 and PPARα knock-out mice, which supports a possible non-peroxisome
proliferators mechanism of action in reproductive organs [14]. This concept of PFOA-
induced non-PPARα mediated toxicity has been demonstrated in an in vivo rainbow trout
model in which the liver tumor promoting activity was related to an estrogenic signaling
mechanism rather than to the ability of PFOA to function as a peroxisome proliferator [32].
Following PFOA administration, hepatic microarray profiles in rare minnows showed
significant induction of estrogen-responsive genes [25] and confirmed earlier findings of
increased expression of vitellogenin and ERβ, and induction of histopathologic changes in
the testes and ovary suggestive of endocrine disruption [33].
The above studies all support the concept that the effects of PFOA may be endocrine-
mediated, possibly through an estrogen signaling mechanism. In the present study, we found
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that exposure of immature mice to low doses of PFOA had minimal but visible estrogenic
effects which occurred primarily in the uterus in the 0.01 PFOA group with fewer effects
observed in the cervix and vagina. Vaginal mucification was noted; however, squamous
hyperplasia and keratinization of the epithelial layers of the cervix and vagina, lesions that
typically occur following exposure to estrogens, such as estradiol and DES [34, 35] were not
observed to any significant extent in the PFOA alone groups. Vaginal mucification has been
reported in neonatal suckling mice exposed to estradiol through the milk [36], in the
offspring of mice transplacentally exposed to estrogens [37], and in rats exposed to the
phytoestrogen, genistein, which is weakly estrogenic [38]. Also, vaginal mucification occurs
in response to exposure to potent androgens [39] or progesterone receptor ligands, such as
the selective progesterone receptor modulator, asoprisnil [40], or following administration of
a combination of E2 and progesterone [41]. PFOA is reported to increase progesterone levels
in mice, and enhance mammary gland receptivity to the effects of exogenous E2 with
upregulation of growth factor expression in the mammary gland [14]. Additional
mechanistic studies are underway to determine the mode of action of PFOA in relation to the
effects observed in this study and to determine if the histopathologic changes observed are
indeed attributable to an estrogen- or progesterone- mediated mechanism, or through
indirect hormonal regulation of other signaling pathways, and/or a hormone independent
pathway.
In conclusion, we have shown that PFOA produces minimal, but significant changes in the
reproductive organs of immature mice. These data suggest that the immature reproductive
tract may be a target for endocrine disrupting compounds that could result in perturbations
in development or may manifest as an adverse outcome later in life. PFOA, when co-
administered with E2, does not appear to interfere with E2-induced effects in the immature
reproductive tract of female CD-1 mice. However, it has been reported that a combination of
PFOA and E2 produced anti-estrogenic effects in cultured tilapia hepatocytes [42]. Future
studies are needed to define the mechanism(s) by which PFOA induces histopathologic
changes in the reproductive organs of immature mice. In addition, because of several animal
studies and the advent of human exposure data that indicate that PFOA can cause endocrine
disruption, more research is needed to determine the importance of time of exposure, low
dose exposures, and the molecular mechanisms by which the endocrine disrupting effects
may occur.
Highlights
We assess whether perfluorooctanoic acid (PFOA) is estrogenic or antiestrogenic.
We use an immature mouse uterotrophic assay and histopathology.
Uterine weights were significantly increased in the 0.01 mg/kg PFOA only group.
Characteristic estrogenic changes were minimally visible in the 0.01 PFOA only mice.
A low dose PFOA does not antagonize the histopathologic effects of E2.
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Uterine wet weight (UWW) for mice receiving varying doses of PFOA treatments once
daily for 3 days from PND18-20. (A) The PFOA dose response on uterine wet weight for
mice not treated with 17 β-estradiol. (B) The PFOA dose response on uterine wet weight for
mice treated with 17 β-estradiol (500 μg/kg/day) for 3 days from PND18-20. **Statistically
significant different from control p<0.05.
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Uterine wet weight to body weight (UWW:BW) ratio of mice that received varying doses of
PFOA once daily for 3 days from PND18–20. (A) The PFOA response on the ratio of mice
not treated with 17 β-estradiol. (B) The PFOA response on the ratio of mice treated with 17
β-estradiol (500 μg/kg/day) for 3 days. **Statistically significant different from control
p<0.05.
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Histopathologic changes in the uterus, cervix and vagina of mice following 0 PFOA
(control), PFOA alone, 17 β-estradiol (E2) alone or PFOA+E2 treatment for 3 days from
PND18–20. (A–C) Control Tissues: Uterus (A); Cervix (B); and Vagina (C). Note no
estrogenic changes in the uterus, cervix and vagina of a control mouse. (D–F) E2 (500 μg/
kg/day) treatment: Uterus (D), note moderate edema of the endometrium (E), endometrial
epithelial (EE) and glandular (EG) hyperplasia, and myometrial (M) hypertrophy; Cervix
(E), note moderate squamous hyperplasia and cornification of the cervical epithelium (CE)
and edema of the stroma (S); and Vagina (F), note moderate squamous hyperplasia and
cornification of the vaginal epithelium (VE) and edema of the submucosa (SM). (G–I)
PFOA treatment (0.01 mg/kg/day): Uterus (G), note minimal edema of the endometrium (E)
with minimal endometrial epithelial (EE) and glandular (EG) hyperplasia and myometrial
(M) hypertrophy and edema; Cervix (H), note absence of squamous hyperplasia and
cornification of the CE and minimal stromal (S) edema; and Vagina (I), note absence of
squamous hyperplasia and cornification of the vaginal epithelium (VE), but presence of
minimal mucification and minimal submucosal (SM) edema.
(J–L) PFOA (0.01 mg/kg/day) + E2: Uterus (J), note moderate edema of the endometrium
(E), endometrial epithelial (EE) and glandular (EG) hyperplasia and myometrial (M)
hypertrophy and edema; Cervix (K) note moderate squamous hyperplasia and cornification
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of the cervical epithelium (CE) and edema of the stroma (S); and Vagina (L), note moderate
squamous hyperplasia and cornification of the vaginal epithelium (VE) and edema of the
submucosa (SM). H & E. 40x, original magnification.
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Comparison of histopathology severity scores for estrogenic changes in the uterus of mice
following 0 (control) to 1.0 PFOA with or without 17 β-estradiol (E2) treatment for 3 days
from PND18–20. H & E stained sections of uterus from immature mice were scored in a
blinded and unbiased manner from 0 to 4 for the extent of estrogenic changes, as described
in the Materials and Methods section. 0–1, indicates no or minimal estrogenic changes, and
4 represents severe estrogenic changes. (A) Endometrial edema, hyperplasia of the
endometrial mucosa (Endometrial Epi Hyper, Mucosa), and glands (Endometrial Epi Hyper,
gland) and edema, hypertrophy and hyperplasia of the myometrium (Myo Edema/
Hypertrophy/Hyper) were scored separately and individually compared between groups. The
numbers indicate mice with lesion over total evaluated. Each category of histopathologic
changes indicated above was compared independently between groups and significant
differences are as indicated: ap<0.01 vs. control; bp< 0.05 vs. 0.1 PFOA alone; cp<0.01 vs.
0.1 PFOA alone; dp<0.05 vs. 1.0 PFOA alone. (B) A mean overall score for estrogenic
changes in the uterus was generated for each group. The numbers indicate total number of
mice evaluated. Significant differences in overall histopathologic changes between groups
are as indicated: bp< 0.05 vs. 0.1 PFOA alone; ep<0.05 vs. control. There were no
statistically significant differences between the E2 treated groups.
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Comparison of histopathology severity scores for estrogenic changes in the cervix and
vagina of mice following 0 (control) to 1.0 PFOA with or without 17 β-estradiol (E2)
treatment for 3 days from PND18–20. H & E stained sections of cervix and vagina from
immature mice were scored in a blinded and unbiased manner from 0 to 4 for the extent of
estrogenic changes, as described in the Materials and Methods section. 0–1, indicates no or
minimal estrogenic changes, and 4 represents severe changes. (A) Squamous hyperplasia
and cornification of the mucosa (Squamous Hyperplasia & Cornification), mucification of
the mucosa (Mucification), and edema of the submucosa or stroma (Edema, Submucosa/
Stroma) were scored separately. The numbers indicate mice with lesion over total number
evaluated. Each category of histopathologic changes indicated above was compared
independently between groups and significant differences are as indicated: ap<0.05 vs.
control. (B) A mean Page overall score for changes in the vagina and cervix was generated
for each group. The numbers indicate total number of mice evaluated. Significant
differences in overall histopathologic changes between groups are as indicated: ap<0.05 vs.
control. There were no statistically significant differences between the E2 treated groups.
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